Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)

Central Hospital, Nancy, France200 enrolled

Overview

New rapid diagnostic strategies are warranted in intra-abdominal candidiasis (IAC). A previous retrospective study showed that one measure, the day of the surgery, of peritoneal 1.3-Beta-D-Glucan ≤ 310pg/ml could rule out an IAC. This strategy was independent of the patient underlying conditions and Candida risk factors. This study aimed to confirm these results with a multicenter prospective study

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Intra Abdominal Infections Candidiasis, Invasive Peritoneal Candidiasis Critically Ill

Interventions

1.3 BETA D GLUCAN

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * critically ill adult (\> 18 yrs old) admitted to ICU for intra-abdominal infection requiring surgery and possible intra abdominal candidiasis Exclusion Criteria: * declinate to participate, * expected death within the first 24 hours

Locations (4)

CHR Mercy

Metz, Lorraine, France

PILI-FLOURY Sebastien

Besançon, France

BOUHEMAD Belaid

Dijon, France

POTTECHER Julien

Strasbourg, France

Outcomes

Primary Outcomes

Measure of 1.3 BDG in the peritoneal exudate of patient with intra-abdominal candidiasis

Value of 1.3 BDG in the peritoneal exudate in patient with intra-abdominal candidiasis in comparison with non intra-abdominal candidiasis

Time frame: 1 DAY

Secondary Outcomes

Measure of 1.3 BDG in the serum of patient with intra-abdominal candidiasis

Coefficient of correlation between peritoneal and serum 1.3 BDG in patient with and without intra-abdominal candidiasis

Time frame: DAY 1 and DAY 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.